A case of denosumab-associated hyperparathyroidism: A differential diagnostic challenge
- 8 October 2021
- journal article
- Published by Peertechz Publications Private Limited in International Journal of Immunotherapy and Cancer Research
Abstract
Denosumab is a relatively new medicine that has become the second option in the treatment of biphosphonate-resistant or intolerant osteoporosis. Subcutaneous injection with 6-month intervals, approval of its usage in stage 3-4 CKD and not having gastrointestinal side effects are advantages of denosumab. However, it has some disadvantages like requiring monitoring serum levels of calcium and vitamin D before each injection.Keywords
This publication has 3 references indexed in Scilit:
- Denosumab-induced Normocalcemic Hyperparathyroidism in a Woman with Postmenopausal Osteoporosis and Normal Renal FunctionCurrent Drug Safety, 2018
- Severe Hypocalcemia Associated With Denosumab in Metastatic Castration-Resistant Prostate Cancer: Risk Factors and Precautions for Treating PhysiciansClinical Genitourinary Cancer, 2014
- Severe Hypocalcemia due to Denosumab in Metastatic Prostate CancerCase Reports in Nephrology, 2014